ALS is a fatal neurodegenerative condition that affects chewing, talking, and walking, progresses to paralysis, and culminates in respiratory failure, typically within three to five years. An estimated 30,000 Americans live with ALS, sometimes called Lou Gehrig’s disease. On Sept. 29, the Food and Drug Administration approved Relyvrio from Amylyx Pharmaceuticals. It’s the first ALS medication to be approved in five years and only one of three currently prescribed to patients to slow the progression of the disease, but should it have been approved?

Scientists are arguing about ‌‌the causes of obesity, which affects more than 40 percent of U.S. adults and costs the health system about $173 billion yearly. The meeting resulted in an implicit understanding of what obesity is not: a personal failing. That is ridiculous and means that we’re going to continue to experience high healthcare costs.

The purpose of any business is to make money, but can a corporation satisfy Wall Street and benefit the public it serves? Big oil, for example, has prioritized profits resulting in high gas prices. Medical expenses often hinder patients long after they have left the hospital. Why do prescription drugs need to cost so much?